Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Western Oncolytics Closes $2.5M Series A to Advance Cancer Immunotherapy

By Drug Discovery Trends Editor | June 22, 2015

Western Oncolytics, a cutting-edge biotechnology company developing a best-in-class oncolytic immunotherapy, has completed a $2.5 million Series A round of funding. The funding will be used to complete preclinical development of its lead therapy, the WO-12.  The WO-12 is designed to deliver multiple immunotherapies in one, while itself selectively infecting and countering cancer.  It holds promise to offer significantly greater safety and efficacy to a wide range of solid tumor cancer patients compared to existing treatments. 
 
The WO-12 is based on the vaccinia virus, the vaccine that eradicated smallpox.  It has been engineered to selectively replicate in only cancer cells, killing them, while drawing an immune response to tumors.  Importantly, it has also been modified to expresses added genes that both specifically activate cancer-fighting T-cells and remove immune inhibition in the tumor environment, two therapeutic approaches that each have had recent clinical successes.  The WO-12 is further modified to avoid premature clearance from the patients’ anti-viral immune response, the limiting factor to oncolytic therapies.  The WO-12 is unique not only in these individual therapeutic elements, but is the only known treatment that combines all of these desired elements into a single therapy.
 
“I am especially excited about WO-12 as a novel oncolytic immunotherapy that will be capable of simultaneously targeting cancer cells through multiple and synergistic mechanisms,” explained Dr. Stephen Thorne, PhD, Professor at the University of Pittsburgh and inventor of Western Oncolytics’ therapy.  “It has been designed to help a wider range of patients than other oncolytic immunotherapies.  It is capable of being delivered by a standard IV and it utilizes an oncolytic virus that can be active in nearly any solid tumor tissue in the human body.  It also combines with other immunotherapies or traditional oncology treatments to further benefit patients.”  
 
Preclinical data indicates WO-12 has significantly greater efficacy than earlier immuno-oncolytics, including the clinically successful GM-CSF class of therapies.  In a comparison study, a WO-12 prototype led to 4 times as many subjects achieving long-term survival as a replica of a clinicallydemonstrated GM-CSF oncolytic.  
 
“Western Oncolytics will be well supported with this experienced group of private investors who bring a wealth of knowledge and share our vision,” said Kurt M. Rote, Chief Executive Officer.  “We aim to deliver this novel therapy to the clinics and change how cancer is treated for the many patients in need.”  
 
Source: Western Oncolytics

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50